Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science (PLoS)
2016-01-01
|
| Sarja: | PLoS ONE |
| Linkit: | http://europepmc.org/articles/PMC4827807?pdf=render |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|